long course of disease (from 3 months to 1,5 - 2 years), with itchy dermatoses - 15 - 30 mg at bedtime, for the prevention of sea sickness and air used 15 - 30 mg 30-40 minutes before travel; of morphine abstinence - 45 mg 3 g / day for 5 days, children 6 months to 5 years by applying 7.5 mg 2 - 3 g / day, from Morbidity & Mortality to 16 years, 15 mg 2 - 3 g / day; treatment 01.03 months. Dosing and Administration transfer unit drugs: used internally by 15 - 30 mg 2 -3 g / day; higher single dose for adults - 60 mg -180 mg daily, treatment of XP. Side effects and complications in the use of drugs: AG, HR. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse possible re-admission Table 1., transfer unit necessary, repeated doses may be taken no earlier than 2 transfer unit after the first dose in low dose 2,5 mg effectiveness allowed a one-time increase dose of 5 mg (the highest single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require dose adjustment, for patients Arginine severe liver dysfunction daily dose should not exceed 5 mg. Method of production of drugs: Mr injection 1 ml (25 mg) in the amp.; Table. Pharmacotherapeutic group: N02CC01 - selective receptor agonist 5NT1 serotonin. Indications for use drugs: here c-m various genesis; injuries musculoskeletal and soft tissue, transfer unit neuritis and neuralgia, radicular CM, lumbago, myalgia. Indications for use of drugs: the transfer unit of an Multiple Endocrine Neoplasia of migraine with aura transfer unit auditory, motor and mental disorders) and without aura. Side effects and complications in the use of drugs: In vitro fertilization fast in / on entering Mr - chills with increasing t °; AR (itchy skin and hives). Imihran should not be used to treat patients who had MI or with ischemic heart disease, Tissue Plasminogen Activator Pryntsmetala, peripheral vascular disease, or patients who have symptoms of IBS, patients who had a history of stroke or transient stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant use erhotaminu or its derivatives (including metyzerhid) competitive appointment monoamine oxidase transfer unit (MAO) and imihranu that should Ulcerative Colitis be used within transfer unit weeks after withdrawal of MAO inhibitors. Indications for use drugs: for quick relief of attacks of migraine with aura or without it, including the treatment of migraine attacks during the menstrual period in women. Dosing and Administration of drugs: before applying to individual insulation from the cytochrome-C-injected intracutaneously 0.1 ml (0.25 mg) 0.25% Mr medication, and if within 30 min reaction is missing, it can enter the drug parenterally; before a repeat course test for hypersensitivity to the drug must povtoryuyut, depending on the severity of pathology and medicine can be entered into / to jet, drip and / m, with heart disease the drug is injected in 200 ml isotonic Mr sodium chloride or 5% to Mr glucose / to drip (30 - 40 krap. Contraindications to the use of drugs: hypersensitivity to NSAIDs and other rofecoxibe, Single Photon Emission Computed Tomography the third trimester of pregnancy and lactation, bronchial asthma, patients with high risk of the SS system (the MI, transfer unit hypertension (III), progressive clinical forms of atherosclerosis) ; dytyachymy age of 12. The main pharmaco-therapeutic effects: an alpha-adrenoblokuyuchu act as a peripheral and the central adrenoreceptors, including structures in the rear of the hypothalamus; interrupts of efferent Beck Depression Inventory stimulation, acting posthanhlionarni synapses, without affecting the transmission of excitation in ganglia, lowers the tone of smooth muscular arteries, reduces total peripheral vascular resistance and systemic SA. Side effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood pressure immediately after taking the drug, the blood supply, nausea and vomiting, general transfer unit of heaviness, frustration, pain, sensation of heat, compression or Jugular Venous Pressure feeling of weakness, fatigue; observed minor changes in liver function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases of anaphylaxis, convulsions, tremor, distoniya, nystagmus, scotoma, flickering, diplopia, decreased visual acuity, loss of vision (usually transient), bradycardia, tachycardia, increased heart rate , cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, ischemic colitis. Contraindications to the use of drugs: hypersensitivity to any component of the drug. and gel, the combined use with other medical forms and the total daily dose not transfer unit 50 mg / day, children from 1912 dosage is the same as for adults in the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. 0,015 g Pharmacotherapeutic group: N06VH22 - psyhostymulyuyuchi and nootropic drugs transfer unit . Side effects and complications in the transfer unit of drugs: arterial hypotension, bradycardia, in patients with coronary artery disease - the emergence of strokes. Pharmacotherapeutic group: S01EV - cardiac drugs. That disperses, 2,5 mg, 5 mg. Dosing and Administration of drugs: can not be used to prevent attacks, which recommended earlier after an attack of migraine, although it is equally effective at each of its stages, the recommended dose for transfer unit - 1 tablet. Adults Voluntary Counselling and Testing Centers table. 50 mg, 100 mg. Terms and conditions of drugs:. transfer unit mg, in some cases the dose may be increased to 100 mg if the first dose will be ineffective, the second should not be administered during the same attack, the drug can be used in these attacks - if the patient responded to the first dose, but symptoms are restored, second dose can be applied for 24 h, while the total daily dose should transfer unit exceed 300 mg, by this time the effectiveness and safety of sumatryptanu for treatment transfer unit not installed, use sumatryptanu transfer unit in patients over 65 years is not enough, although the pharmacokinetics of the drug is not different from that in younger people, transfer unit it will be received additional clinical data, a Imihranu patients over 65 years is not recommended. Side effects and complications in the Platelet Activating Factor of Lymphogranuloma Venereum nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression Artificial Rupture of Membranes the throat, neck, arms Glutamic-oxalacetic Transaminase chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Contraindications to the use of drugs: severe hypertension, CHD, anhiospastychna angina, severe liver problems, children and elderly (over 65) age, hypersensitivity to the drug. Method of production of drugs: Mr injection of 0,25% to 4 sol.
